Three years after it was formed as a spinout of Japanese drugmaker Takeda, Phathom Pharmaceuticals has racked up its first FDA approvals, and claimed a sizeable $260 million in new financin
Bristol-Myers Squibb’s Zeposia (ozanimod) is already tipped for blockbuster sales in its first indication – multiple sclerosis – and new data in ulcerative colitis suggests they could climb
None of the immune-modulating drugs approved to treat ulcerative colitis – even biosimilars – are priced low enough to be cost-effective, says the Institute for Clinical and Economic Review
Japan’s Takeda has posted a surprise profit after its $59 billion merger with Shire just over a year ago, as the company shakes off the huge debts it incurred to get the deal done.
Ferring Pharma has reported what it says is the first positive phase 3 trial of a microbiome therapy – based on healthy bacteria – showing it can reduce recurrences of a seriou
Eleven new digital health start-ups have graduated from PharmStars’ twice-yearly education and mentoring programme, with the latest crop focusing on digital innovations in
On 1st October, the roll-out of the National Contract Value Review (NCVR) process marked a pivotal moment in the trajectory of clinical research in the UK, introducing a standardised, natio